OBJECTIVES: To study overall survival (OS), prognostic factors, and repeated surgery in glioblastoma multiforme (GBM). MATERIAL AND METHODS: Retrospective study of 516 consecutive adult patients who underwent primary surgery for a GBM in year 2003-2008. RESULTS: Median age at primary surgery was 63.7 years (range 18.0-88.0). Median OS was 9.9 months. Age > 60 years, poor preoperative ECOG score, bilateral tumor, biopsy rather than resection, and no temozolomide chemoradiotherapy were negative risk factors. Repeat surgery was performed in 65 patients (13%). Median time between first and second surgery was 7 months. Indications for second surgery were increasing neurological deficits (35.4%), raised ICP (33.8%), asymptomatic but reoperated because of tumor progression verified on MRI (20.0%), and epileptic seizures (11%). Patients who underwent repeated surgery had longer OS; 18.4 months vs 8.6 months (P < 0.001). CONCLUSIONS: OS for adult GBM patients was 9.9 months. Negative prognostic factors were increasing age, poor neurological function, bilateral tumor involvement, biopsy instead of resection, and RT alone compared to temozolomide chemoradiotherapy. Our rate of repeated surgery for GBM was 13% and the main indications for second surgery were raised ICP and increasing neurological deficits. In a carefully selected group of patients, repeat surgery significantly prolongs OS.
OBJECTIVES: To study overall survival (OS), prognostic factors, and repeated surgery in glioblastoma multiforme (GBM). MATERIAL AND METHODS: Retrospective study of 516 consecutive adult patients who underwent primary surgery for a GBM in year 2003-2008. RESULTS: Median age at primary surgery was 63.7 years (range 18.0-88.0). Median OS was 9.9 months. Age > 60 years, poor preoperative ECOG score, bilateral tumor, biopsy rather than resection, and no temozolomide chemoradiotherapy were negative risk factors. Repeat surgery was performed in 65 patients (13%). Median time between first and second surgery was 7 months. Indications for second surgery were increasing neurological deficits (35.4%), raised ICP (33.8%), asymptomatic but reoperated because of tumor progression verified on MRI (20.0%), and epileptic seizures (11%). Patients who underwent repeated surgery had longer OS; 18.4 months vs 8.6 months (P < 0.001). CONCLUSIONS: OS for adult GBM patients was 9.9 months. Negative prognostic factors were increasing age, poor neurological function, bilateral tumor involvement, biopsy instead of resection, and RT alone compared to temozolomide chemoradiotherapy. Our rate of repeated surgery for GBM was 13% and the main indications for second surgery were raised ICP and increasing neurological deficits. In a carefully selected group of patients, repeat surgery significantly prolongs OS.
Authors: Xianyuan Song; R Andrew Allen; S Terence Dunn; Kar-Ming Fung; Peter Farmer; Shital Gandhi; Tulika Ranjan; Alexis Demopoulos; Marc Symons; Michael Schulder; Jian Yi Li Journal: Int J Clin Exp Pathol Date: 2011-09-17
Authors: Matt Williams; Zi Wei Liu; David Woolf; Sarah Hargreaves; Vasiliki Michalarea; Rebecca Menashy; Ishminder Kooner; Elena Wilson Journal: J Cancer Res Clin Oncol Date: 2012-05-27 Impact factor: 4.553
Authors: Debra A Goldman; Koos Hovinga; Anne S Reiner; Yoshua Esquenazi; Viviane Tabar; Katherine S Panageas Journal: J Neurosurg Date: 2018-11-01 Impact factor: 5.115
Authors: Joshua D Palmer; Joshua Siglin; Kosj Yamoah; Tu Dan; Colin E Champ; Voichita Bar-Ad; Maria Werner-Wasik; James J Evans; Lyndon Kim; Jon Glass; Christopher Farrell; David W Andrews; Wenyin Shi Journal: J Neurooncol Date: 2015-05-30 Impact factor: 4.130
Authors: Ridwan Alam; Chad R Schultz; William A Golembieski; Laila M Poisson; Sandra A Rempel Journal: Neuro Oncol Date: 2013-02-03 Impact factor: 12.300